Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727169 | 0.85 | PPM1B (0.74) | PPM1BKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16374369 | 0.81 | PPM1B (0.72) | PPM1BKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL3924044 | 0.81 | PPM1B (0.68) | PPM1BKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL12040442 | 0.80 | ALDH1A1 (0.70) | PPM1BKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL3495475 | 0.78 | ALDH1A1 (0.76) | PPM1BKMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL728496 | 0.76 | POLB (0.74) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL9013063 | 0.74 | ALDH1A1 (0.59) | PPM1BKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL726901 | 0.74 | FPR2 (1.00) | PPM1BKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL726819 | 0.72 | FPR2 (1.00) | ALDH1A1PKMFPR2 | |
| SCHEMBL23823001 | 0.72 | ALDH1A1 (0.57) | PPM1BKMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163502-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | FPR1, FPR2, FPR3 | PPM1B 4595/4885KMT2A 4493/4885MEN1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.